Background Long-term clinical effectiveness of biologics in psoriasis is needed. Objectives We aimed to assess the long-term persistence of biologics used to treat psoriasis in a real-life setting. Methods All adults with psoriasis having been registered in the French National Health Insurance database (SNIIRAM) between 2008 and 2016 were eligible for inclusion. Psoriasis was defined as the fulfilment of at least two prescriptions for topical formulations of a vitamin D derivative within a 2-year period. The study population comprised biologic-na€ ıve patients, i.e. those with a first prescription of etanercept, infliximab, adalimumab or ustekinumab. Persistence of treatment with a biologic was defined as the time interval between initiation and discontinuation. Results In this nationwide population-based cohort, 16 545 out of 874 549 patients with psoriasis were biologic-na€ ıve (mean age 48Á6 years; males 57Á3%, mean follow-up 3Á6 years). The mean AE SD length of follow-up for biologicna€ ıve patients was 3Á6 AE 2Á4 years. There were 9988 treatment discontinuations. Kaplan-Meier survival analyses revealed a persistence rate of 61Á9% for the first, 33Á3% for the third and 22Á6% for the fifth year. Ustekinumab had a higher persistence rate than the other biologics. This finding should be interpreted with caution, in view of differences in administration between the biologics. About 85% of patients, having discontinued their first biologic, resumed systemic treatment of some type in the following year (biologics in 85% of cases). Conclusions Our data suggest that biologics are less effective than physicians have been led to believe in a real-life, nonselected population. Further, long-term disease control requires several courses of different biologics.
Summary
Background Long-term clinical effectiveness of biologics in psoriasis is needed. Objectives We aimed to assess the long-term persistence of biologics used to treat psoriasis in a real-life setting. Methods All adults with psoriasis having been registered in the French National Health Insurance database (SNIIRAM) between 2008 and 2016 were eligible for inclusion. Psoriasis was defined as the fulfilment of at least two prescriptions for topical formulations of a vitamin D derivative within a 2-year period. The study population comprised biologic-na€ ıve patients, i.e. those with a first prescription of etanercept, infliximab, adalimumab or ustekinumab. Persistence of treatment with a biologic was defined as the time interval between initiation and discontinuation. Results In this nationwide population-based cohort, 16 545 out of 874 549 patients with psoriasis were biologic-na€ ıve (mean age 48Á6 years; males 57Á3%, mean follow-up 3Á6 years). The mean AE SD length of follow-up for biologicna€ ıve patients was 3Á6 AE 2Á4 years. There were 9988 treatment discontinuations. Kaplan-Meier survival analyses revealed a persistence rate of 61Á9% for the first, 33Á3% for the third and 22Á6% for the fifth year. Ustekinumab had a higher persistence rate than the other biologics. This finding should be interpreted with caution, in view of differences in administration between the biologics. About 85% of patients, having discontinued their first biologic, resumed systemic treatment of some type in the following year (biologics in 85% of cases). Conclusions Our data suggest that biologics are less effective than physicians have been led to believe in a real-life, nonselected population. Further, long-term disease control requires several courses of different biologics.
What's already known about this topic?
• Psoriasis is a common, chronic, relapsing, inflammatory skin disease associated with severe psychosocial impact.
• Biological treatments appear to be highly effective for inducing short-term remission in a selected-trial population of patients with psoriasis.
• There is much less evidence of the long-term clinical effectiveness of these biological treatments.
What does this study add?
• The persistence of treatment with biologics is low in a large real-life, nonselected population of patients (overall persistence rate was 61% the first year, and it fell markedly over time, with a persistence rate of 33% at the end of the third year and 22% at the end of the fifth year).
• Eighty per cent of patients who had stopped taking their first-ever biologic started taking another systemic treatment (a biologic, in 85% of cases) within 6 months of cessation.
• Long-term disease control requires several courses of different biologics.
Over the past two decades, a better pathophysiological understanding of psoriasis has led to the identification of new drug targets and the development of biologics.
1 A recent Cochrane review has found that biologics are more efficacious than conventional, systemically administered drugs (such as methotrexate or ciclosporin) in a selected population of patients with moderate-to-severe psoriasis. 2 However, the evidence is limited to the induction phase (from 12 to 16 weeks) and is not sufficiently relevant to chronic disease. Nast et al. performed a network meta-analysis of trials in which treatments were assessment for at least 24 weeks. 3 Interestingly, the efficacy levels of biologics were maintained over time. However, this finding still corresponds to a relatively short-term time frame (24 weeks) for a disease that can persist for many years. Moreover, clinical trial participants are subject to inclusion and noninclusion biases (becoming increasingly stringent), which limits the ability to extrapolate trial results. [4] [5] [6] Therefore, although biologics appear to be highly effective for inducing short-term remission in a selected population of patients with psoriasis, there is much less evidence of the long-term clinical effectiveness of biologics in this setting. Treatment persistence (defined as the time interval between treatment initiation and discontinuation) is a relevant indicator of the patient's level of interest. 7 This parameter integrates effectiveness (because a treatment perceived as being ineffective will not be continued) and safety (because a poorly tolerated treatment is likely to be discontinued). Persistence is similar to the judgement criteria typically applied in pragmatic trials. 8 This parameter is attracting growing interest in the field of dermatology, where most studies have looked at the persistence of treatment with biologics in patients suffering from psoriasis. 9-13 However, these studies were limited by selective recruitment of the study population (in a postmarketing commitment study 12 ) or the small number of enrolled patients. 10, 11, 13 The main objective of the present study was therefore to assess and compare the long-term persistence of several different biologics used to treat psoriasis in a large, exhaustive, nonselected population of patients in France. This study was approved by the French data protection agency Commission Nationale de l'Informatique et des Libert es (regulatory decision DE-2015-165).
Methods

Data sources
This French, nationwide cohort study was based on health administrative data obtained from the French National Health Insurance general scheme covering approximately 65 million individuals linked with the national hospital discharge database (SNIIRAM-PMSI) by means of a unique anonymous identifier, as previously described.
14-16
Study population and follow-up procedures All adults (≥ 18 years of age) with psoriasis registered in the SNIIRAM between 1 January 2008 and 31 December 2016 were eligible for inclusion. Adults with psoriasis were identified by the prescription of at least two topical vitamin D derivatives (ATC D05AX, the recommended first-line treatment for psoriasis in France) within a 2-year period. 17 The date of inclusion in the study cohort (index date) was defined as the date of the second fulfilment of the topical vitamin D prescription. Participants were followed up until 31 December 2016 or the censorship dates (death or loss to follow-up, defined by the absence of prescription fulfilments for 12 consecutive months). Patients with at least one prescription of a systemic medication for psoriasis were identified. These treatments included conventional medications (acitretin, ATC D05BB02; ciclosporin, L04AD01; methotrexate, L01BA01 or L04AX03) and biologics/biosimilars (etanercept, L04AB01; infliximab, L04AB02; adalimumab, L04AB04; ustekinumab, L04AC05). Lastly, the final analysis set comprised biologicna€ ıve patients, defined as those who had fulfilled a first prescription of etanercept, infliximab, adalimumab or ustekinumab after 2 years without any biologics during the study period.
Outcome and definitions
For each biologic-na€ ıve patient in the study population, the persistence of treatment with a biologic was defined as the length of time from initiation to discontinuation. We defined the discontinuation of treatment as a period of more than 90 days without fulfilment of a prescription for the same treatment after the period covered by the previous prescription. 10 The treatment regimen differed markedly from one biologic to another. In fact, the period covered by a prescription was 30 days for etanercept and adalimumab, 56 days for infliximab, and 84 days for ustekinumab. Exposure to combinations of drugs was defined as a period of less than 30 days between the prescription of two different systemic drugs and the fulfilment of another prescription for both drugs in the following 90 days.
Covariables
For each biologic-na€ ıve patient, the age at the index date and at the initiation date, sex, associated inflammatory diseases [psoriatic arthritis (PsA) and inflammatory bowel disease (IBD)] and comorbidities [hypertension, diabetes, dyslipidaemia, major adverse cardiovascular events, hepatic disease, renal disease, asthma, chronic obstructive pulmonary disease (COPD) and cancer] were recorded for the 2-year period before the date of first exposure to a biologic. These covariables are defined in Supplementary  Table S1 . Data on exposure to conventional systemic treatments in the 2 years preceding the initiation of a biologic were also recorded.
Statistical analysis
For descriptions of the study population, qualitative variables were reported as the number (percentage). Quantitative variables were reported as the median and/or the mean AE SD or were converted to qualitative variables.
To ensure the accuracy of our criterion for a diagnosis of psoriasis, we assessed the sensitivity in a population having received at least one fulfilment of ustekinumab in 2012; in France, this drug was reimbursed only in cases of physiciandiagnosed psoriasis from 2010 to 2015.
Change in persistence over time was estimated for all biologics together and for each biologic, using the Kaplan-Meier method. Multivariate Cox proportional hazard models were used to calculate the adjusted hazard ratio (aHR) [two-sided 95% confidence interval (CI)] for predictive factors for the persistence of biologics in psoriasis. The proportional hazard assumption was tested formally using Schoenfeld residuals. Lastly, for biologic-na€ ıve patients having discontinued their first course of systemic treatment before 31 December 2015, we calculated the proportion having received a conventional systemic treatment, a biologic or no treatment in the 12 months following the discontinuation.
Sensitivity analyses were performed to add robustness to the results. As mentioned above, the maintenance-phase treatment regimen differed markedly from one biologic to another: a weekly injection for etanercept, every other week for adalimumab, every 6-8 weeks for infliximab, and every 12 weeks for ustekinumab. These differences in frequency might lead to overestimation of the persistence for infliximab and ustekinumab. Indeed, a physician would assess the efficacy of ustekinumab after the third injection, i.e. after at least 6 months of treatment, whereas he would assess the efficacy of adalimumab or etanercept after 3-4 months of treatment. We therefore performed a sensitivity analysis on a subset of confirmed persistent patients (i.e. patients who received at least 9 months of continuous treatment with biologics). Details on other sensitivity analyses are provided in Supplementary Appendix S1.
Data were analysed using SAS Enterprise Guide 7.1 (SAS Institute Inc., Cary, NC, U.S.A.) and the 'newsurv' macro developed by Meyers. 18 All tests were two-tailed, and the threshold for statistical significance was set to P < 0Á05.
Results
Patients with psoriasis
A total of 874 549 patients were identified as having psoriasis (mean AE SD age 53Á8 AE 17 years; males 52Á4%); 112 969 of these patients had fulfilled at least one prescription for a systemic medication used to treat psoriasis. In 2012, 1953 patients had received at least one prescription of ustekinumab, and 1652 of these had received at least two prescriptions of topical vitamin D derivatives within a 2-year period between 2006 and 2012. This gave a sensitivity of 84Á5% for our definition of psoriasis.
Biologic-na€ ıve patients with psoriasis
A total of 16 545 biologic-na€ ıve patients were identified (mean age 48Á6 AE 13Á5 years; males 57Á3%; mean followup time: 3Á6 AE 2Á4 years; Table 1 ). The change over time in the number of biologic-na€ ıve patients on each drug is shown in Supplementary Figure S1 , and the main characteristics of this analysis set are summarized in Table 1 . PsA was listed for 33Á6% of the biologic-na€ ıve patients. We found that 27Á5% of the biologic-na€ ıve patients had not received any conventional systemic treatments in the previous 2 years. The type of concomitant treatments at baseline (mostly methotrexate) were listed for 15Á9% of the biologic-na€ ıve patients.
Persistence of biologics among biologic-na€ ıve patients
During the follow-up period, 9988 biologic-na€ ıve patients discontinued their treatment. Kaplan-Meier survival analyses revealed a persistence rate (95% CI) of 62% (61-63%) for biologics in the first year of treatment ( Supplementary  Fig. S2A and Table S2 ). The persistence rate decreased over time (33% at the end of the third year and 23% at the end of the fifth year; Supplementary Fig. S2A and Supplementary Table S2 ). The survival persistence over time for each biologic is described in Supplementary Table S2 . Similar results for persistence were obtained in sensitivity analyses (Supplementary Fig. S2B-D) .
Comparisons of biologics, and factors associated with the persistence of systemic treatments Table 2 and Figure 1 summarize the Kaplan-Meier analyses for each biologic for the main analysis (the period covered plus a 90-day gap) and for the sensitivity analyses (including confirmed persistent patients). Adalimumab was taken as the reference standard for comparison with the other biologics because it was the most commonly prescribed biologic in our study population. The multivariate Cox model met the assumption of proportionality. The overall multivariate model showed that treatment with etanercept [aHR (95% CI) = 1Á23 (1Á18-1Á29)], treatment with infliximab [aHR (95% CI) = 1Á08 (1Á01-1Á15)], age under 30 years, female sex, asthma or COPD, hypertension, diabetes and treatment with ciclosporin were predictors of discontinuation, whereas treatment with ustekinumab [aHR (95% CI) = 0Á46 (0Á42-0Á49)], PsA, IBD and combination treatment were predictive of persistence (Table 2 ). Sensitivity analysis of confirmed persistent patients (i.e. patients having been continuously treated with a biologic for at least 9 months) also gave a higher persistence rate for ustekinumab than for the other biologics; however, the effect size associated with ustekinumab differed [HR (95% CI) = 0Á51 (0Á48-0Á55) for the whole cohort and 0Á71 (0Á65-0Á78) for the confirmed persistent patients; Fig. 1 ].
The results of other sensitivity analyses are available in Supplementary Appendix S1 and Supplementary Figure S3 .
One-year follow-up data for biologic-na€ ıve patients who discontinued their first course of biologic
More than 80% of patients having discontinued their first biologic started a new course of systemic medication during the subsequent year (Tables 3 and 4) ; 93% of these patients started during the following 6 months. About 85% of these patients started to take another biologic (the same biologic as before in 30% of these cases, and a different biologic in the remaining 70%).
Discussion
In this French, nationwide study based on the SNIIRAM National Health Insurance database, we sought to assess the long-term persistence of biologics used to treat psoriasis in a large, nonselected population of patients. We focused on biologic-na€ ıve patients. In the first year, the overall persistence rate for biologics was 61%, with values ranging from 53% for anti-tumour necrosis factor (anti-TNF) agents to 85% for ustekinumab. The persistence rate fell markedly over time, with a persistence rate of 33% at the end of the third year and 22% at the end of the fifth year. After adjusting for potentially relevant individual risk factors (i.e. age, sex, comorbidities, PsA, and exposure to conventional systemic treatments and combination treatments), ustekinumab was found to have a higher persistence rate than the other biologics. However, the ustekinumab persistence rate in the whole cohort differed from that in a subgroup of confirmed persistent patients (i.e. patients having been continuously treated with a biologic for at least 9 months), making it difficult to interpret the effect of the molecule per se (independently of its different administration procedure). Lastly, 80% of patients who had stopped taking their first-ever biologic started taking another systemic treatment (a biologic, in 85% of cases) within a year of cessation. All the 1-year persistence rates measured here (including the rate for ustekinumab) were lower than the literature values. 10, 12, 13 This disparity increased over time; in the literature, the 3-year persistence rates are between 40% and 60% for anti-TNF agents and between 75% and 80% for ustekinumab. 10, 12 The corresponding values in the present study were 25-30% for anti-TNF agents and around 55% for ustekinumab. The national population samples in the literature ranged from 1000 to 3500, and so might have been subject to selection bias. 10, 12, 13 These sample sizes were smaller than our study population (16 545 patients included), which might limit extrapolation of the literature data. Garcia-Doval et al. reported that one-third of patients receiving systemic therapy for psoriasis in their national cohort were ineligible for randomized controlled trials (RCTs). 19 Similarly, the representativeness of patients included in the national cohort may be questioned. National cohorts have a number of inclusion criteria, and inclusion in a national cohort is not mandatory for the prescription and reimbursement of psoriasis treatments. 19, 20 Performing a large, exhaustive study of reimbursement data from a nonselected population avoids this selection bias. Nevertheless, the databases analysed in the present study did not specify why a patient had ceased to fulfil prescriptions for a biologic. We found that around 80% of these patients re-initiated systemic treatment (a biologic in 90% of these cases) within the following 6 months, making the hypothesis of loss of drug efficacy plausible. However, differences in healthcare organization between countries, extrinsic factors such as a broader range of treatment options or lower price for biosimilar products could also explain the drug discontinuation. Thus, we performed sensitivity analyses on patients included in the cohort after 1 January 2014 (i.e. 4 years after the approval of the most recently commercialized biologic). The Kaplan-Meier curves for the overall patient population and for the patient population included after 2014 did not differ significantly -indicating that the year in which the drug was reimbursed did not influence the persistence of biologics. Loss to follow-up in national cohort studies might be another source of bias.
In previous studies using a Cox model, patients lost to follow-up were censured. 10, 12, 13 However, the proportion lost to follow-up and the mean duration of follow-up were not reported. Persistence is probably lower in patients lost to follow-up than in patients who are still being followed up. Thus, one cannot rule out the overestimation of the persistence rate in the literature studies. No loss to follow-up was observed in our present database study. The persistence rate for ustekinumab observed in the present study of biologic-na€ ıve patients was in line with the literature data. [10] [11] [12] [13] The higher value associated with ustekinumab (relative to anti-TNF agents) may be due to the antibody's greater short-term effectiveness in RCTs, 21 lower levels of immunogenicity, 22 a lower adverse event rate 23 and a more patient-friendly administration procedure. However, the effect size for ustekinumab in the whole cohort (HR = 0Á5) differed significantly from that seen in the subset of confirmed persistent patients (i.e. those having received at least 9 months of continuous treatment with biologics; HR = 0Á7). In fact, our analysis of the confirmed persistent patients took account of the effect of ustekinumab's more patient-friendly administration procedure, which had artificially overestimated the persistence rate in the main analysis. We cannot rule out the possibility that the higher persistence rate for ustekinumab was related to its administration procedure, rather than the drug's pharmacological action per se. As we were not able to correct for interdrug differences in the length of the administration protocol (e.g. for ustekinumab) after 9 months of our study, we consider that persistence is not the most appropriate endpoint for comparing drugs with very different protocols. 24 Lastly, we found that female sex and certain comorbidities (COPD, hypertension and diabetes) were predictive of poor persistence, whereas PsA or IBD and combination treatment at baseline were predictive of good persistence (as previously reported). 10, 11 The potential severity of associated inflammatory diseases leading to a major functional disability could explain the better drug persistence for these patients. Lastly, the immunomodulating effect of methotrexate and its ability to reduce the immunogenicity of biologic agents could explain this result. Table 5 summarizes the main item for drug persistence in psoriasis from other published studies.
As mentioned above, the strengths of the present study included the large, unbiased sample from a nationally representative database, and the 9-year study period. Limitations The subset of 'good' responders, i.e. confirmed persistent patients (i.e. patients who received at least 9 months of continuous treatment with biologics) (n = 7883). Total, the number of biologic-na€ ıve patients; Event, the number of biologic-na€ ıve patients who discontinued their treatment; Median: the time (in years) until 50% of the biologic-na€ ıve patients had achieved the event; HR, unadjusted hazard ratio; CI, confidence interval. included the absence of direct, clinical information on cases of psoriasis. Our definition of psoriasis was based on the prescription of at least two topical vitamin D derivatives. The latter drugs constitute the first-line treatment for psoriasis, 25 our definition has been validated in a study of a Danish health insurance database by Egeberg et al. 26 and our study population had much the same characteristics as previously described populations of patients with severe psoriasis. 27 It must be borne in mind that some of the biologic-na€ ıve patients defined above may have received a biologic at an undocumented moment before the start of the study. We also limited classification bias by using a reproducible, well-accepted definition of drug persistence. 28 A second limitation is that despite our adjustments for patient-related risk factors associated with persistence of treatments, the presence of residual confounding effects cannot be ruled out. Indeed, data on the severity of psoriasis and other potentially confounding factors (such as tobacco use, alcohol intake and body mass index) were not recorded in our databases. To avoid channelling bias (i.e. a confounding effect of assessing certain treatments in specific subgroups), we limited our analyses to biologic-na€ ıve patients receiving systemic treatment (ustekinumab was used as a second-or third-line treatment in the months following its marketing approval). In summary, our real-world data show that biologics in psoriasis are less effective than initially expected -especially in a nonselected population. Furthermore, long-term disease control requires several courses of the same biologic or of different biologics. This warrants the need for 'therapeutic strategy studies', and highlights unmet medical needs and the requirement for guidelines in the maintenance treatment of psoriasis, including: (i) the adjustment of treatment for patients with stable, low disease activity; (ii) add-on treatments or switches for patients who fail to respond to systemic treatment; and (iii) long-term safety data.
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